Employing circRNA Durability to Sustain Therapeutic Protein Expression in Fibrosis

• Demonstrating sustained circRNA-driven protein and peptide expression in fibrosis to explore where greater durability can reduce repeat administration and improve therapeutic effect
• Leveraging microneedle patch delivery into the dermis to generate strong immune responses at lower RNA doses while enabling simpler, potentially at-home administration
• Comparing circRNA with conventional linear mRNA across therapeutic and vaccine applications to understand how expression duration, dose and route of administration translate into reduced treatment burden

Speakers:

Peter Weinstein

Chief Executive Officer

Circurna